A3P Biomedical appoints Andreas Hoel as new VP of Marketing & Sales
November 1, 2022
A3P Biomedical has appointed Andreas Hoel as VP Marketing & Sales. Andreas Hoel brings more than 20 years´ experience from marketing and sales positions in the life science, diagnostics and medical device industries, most recently at Thermo Fisher in the UK. He joins A3P today and reports to CEO David Rosén.
“I am very pleased that we have been able to recruit Andreas Hoel as our new VP Marketing & Sales. With broad experience from the industry and several challenging positions managing sales and marketing teams, Andreas will be a key member of the management team when we accelerate our commercialization efforts in Europe,” says David Rosén CEO of A3P Biomedical.
“I really look forward to leveraging my experience from the diagnostics industry to broaden the use of Stockholm3. The clinical evidence is very strong, showing that Stockhokm3 can significantly improve the care of prostate cancer patients by finding more cases of aggressive cancer and at the same time reduce overtreatment. This has the potential to save lives, improve the quality of life for the patients and at the same time save money for the healthcare system, which is a highly attractive proposition,” says Andreas Hoel.
Andreas Hoel is 48 years old and holds an M.Sc. in Chemistry from the Technical University of Denmark and an MBA from Henley Management College. Most recently he has served as Senior Director Customer Experience at Thermo Fisher Scientific. Previously he has, for example, been commercialization lead for Thermo Fisher products, been responsible for diagnostic product lines at Dako and served as sales manager and product manager at Biotage.
About A3P Biomedical
A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.
Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.
Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.
About prostate cancer
Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.
Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328